Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ascorbic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.78 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.50 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.50 |
| ▸ | TST | Q16762 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 2/20 | 0.41 |
| ▸ | MANBA | O00462 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ascorbic Acid SCHEMBL408448 | 0.97 | MAPT (0.78) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL7086565 | 0.94 | MAPT (0.73) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL21372602 | 0.92 | LMNA (0.81) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL15226289 | 0.92 | MAPT (0.86) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL17457572 | 0.91 | MAPT (0.69) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL5968922 | 0.90 | MAPT (0.83) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL10642367 | 0.90 | MAPT (0.83) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL31356983 | 0.90 | MAPT (0.83) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL29857583 | 0.90 | MAPT (0.83) | MAPTLMNAL3MBTL1HSPD1HSPE1 | |
| Ascorbic Acid SCHEMBL4087692 | 0.90 | MAPT (0.83) | MAPTLMNAL3MBTL1HSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118696987-A | Nutritional composition and preparation method and application thereof | 美赞臣营养品(香港)有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118696987-A | Nutritional composition and preparation method and application thereof | 美赞臣营养品(香港)有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-116490598-A | Detergent compositions with enhanced efficacy delivery of substances | 株式会社LG生活健康 | 2023-07-25 | — | — | CN | disclosed |
| CN-107072902-B | Use of cosmetic compositions comprising 10-hydroxystearic acid | 帝斯曼知识产权资产管理有限公司 | 2021-01-19 | — | — | CN | disclosed |
| US-9173836-B2 | Pharmaceutical preparations for treatments of diseases and disorders of the breast | FemmeParma Holding Company, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140099383-A1 | Topical Dermal Formulations | FIBROCELL TECHNOLOGIES, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| EP-2608768-A2 | TOPICAL DERMAL FORMULATIONS | Fibrocell Technologies, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120219634-A1 | TOPICAL DERMAL FORMULATIONS | FIBROCELL TECHNOLOGIES, INC. | 2012-08-30 | — | — | US | disclosed |
| WO-2012030716-A1 | PHARMACEUTICAL PREPARATIONS FOR TREATMENTS OF DISEASES AND DISORDERS OF THE BREAST | FEMMEPHARMA HOLDING COMPANY, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012027742-A2 | TOPICAL DERMAL FORMULATIONS | FIBROCELL TECHNOLOGIES, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110212934-A1 | PHARMACEUTICAL PREPARATIONS FOR TREATMENTS OF DISEASES AND DISORDERS OF THE BREAST | FEMMEPHARMA HOLDING COMPANY, INC. | 2011-09-01 | — | — | US | disclosed |
| US-7812010-B2 | Pharmaceutical preparations for treatments of diseases and disorders of the breast | FEMMEPHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100184693-A1 | METHODS AND SYSTEMS FOR GENERATING AND EVALUATING PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2010-07-22 | — | — | US | disclosed |
| US-7739055-B2 | Methods and systems for generating and evaluating peptides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1578421-A4 | PHARMACEUTICAL PREPARATIONS FOR TREATMENTS OF DISEASES AND DISORDERS OF THE BREAST | FEMMEPHARMA HOLDING CO INC (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20070197773-A1 | Methods and Systems for Generating and Evaluating Peptides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2007-08-23 | — | — | US | disclosed |
| WO-2007061850-A2 | METHODS AND SYSTEMS FOR GENERATING AND EVALUATING PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1578421-A2 | PHARMACEUTICAL PREPARATIONS FOR TREATMENTS OF DISEASES AND DISORDERS OF THE BREAST | FemmePharma Holding Company, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040229813-A1 | Pharmaceutical preparations for treatments of diseases and disorders of the breast | FEMME PHARMA, INC. | 2004-11-18 | — | — | US | disclosed |
| WO-2004060322-A2 | PHARMACEUTICAL PREPARATIONS FOR TREATMENTS OF DISEASES AND DISORDERS OF THE BREAST | FEMMEPHARMA HOLDING COMPANY, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184693-A1 | METHODS AND SYSTEMS FOR GENERATING AND EVALUATING PEPTIDES | STING1, VIP, MICA | MAPT 4705/4885LMNA 4187/4885L3MBTL1 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.